ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Digital momentary symptom and food-tracking could help people with IBS or IBD-IBS identify personal triggers and tailor lifestyle or treatment choices, potentially reducing abdominal pain and improving quality of life.
The study tests whether providing personalized app-generated reports to patients and clinicians at a clinic visit changes symptom scores at 12 weeks.
Who Should Pay Attention
Adults with IBS or IBD who experience abdominal pain or IBS-like symptoms; gastroenterologists and primary clinicians treating functional symptoms in IBD; researchers of digital health and personalized symptom management.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment120 participants
Study statusActive_not_recruiting
Source depthTrial registry record
What To Know
This is a registered interventional trial testing whether momentary symptom and food-tracking apps (ESM and Traqq) can help people with IBS and IBD-IBS identify personal triggers for abdominal pain and guide treatment decisions during routine outpatient care.
Participants use the apps for one week; clinicians receive individualized reports before a follow-up visit, and symptom scores are reassessed at 12 weeks. The study is a single-center, randomized, non-blinded proof-of-concept trial comparing an ESM/Traqq intervention plus usual care versus standard care alone.
The trial evaluates change in IBS-SSS and secondary measures of quality of life, anxiety/depression, visceral sensitivity, and fatigue.
If you’re in the intervention arm and later referred to a dietitian or psychologist, you can consent to share your app data to personalize therapy; the protocol does not mandate specific treatments—decisions remain shared between patient and clinician.
Keep In Mind
This is a proof-of-concept, single-center randomized trial registered at ClinicalTrials.gov (ACTIVE_NOT_RECRUITING); the record describes planned procedures and outcomes but does not contain trial results. The protocol relies on shared decision-making for subsequent treatment choices, so any benefits depend on actions taken after receiving the app-generated insights.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorMaastricht University Medical Center
Trial IDNCT05998577
Study typeInterventional
Trial phaseNA
Enrollment120 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 8, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Bidirectional Brain-Gut Signaling in the Persistence of IBS-like Symptoms in Inflammatory Bowel Disease
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...
Incremental Value of Traditional Chinese Medicine Features in Two-Stage Pre-Endoscopic Prediction
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
Trial of Mirtazapine for Depression in IBD
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...